Bank of New York Mellon
TLIS

Bank of New York Mellon’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Bank of New York Mellon’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,497
Closed -$74K – 4723
2022
Q1 		$74K Sell
3,497
-139
-4% -$4.81K ﹤0.01% 4462
2021
Q4 		$219K Sell
3,636
-2,220
-38% -$166K ﹤0.01% 4243
2021
Q3 		$550K Buy
5,856
+190
+3% +$25.3K ﹤0.01% 3761
2021
Q2 		$938K Buy
5,666
+337
+6% +$57.2K ﹤0.01% 3461
2021
Q1 		$1.03M Buy
+5,329
New +$1.33M ﹤0.01% 3314

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon's TLIS Position: Q2 2022 in Review

Bank of New York Mellon sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q2 2022, closing a stake of 3,497 shares — an estimated $74K sold.

Bank of New York Mellon first reported a position in TLIS in Q1 2021 and held it in 5 quarters. The position peaked at $1.03M in Q1 2021. 35 funds tracked by Wall St. Rank hold TLIS as of Q2 2022.

  • Bank of New York Mellon reported no remaining Talis Biomedical Corporation Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 3,497 Talis Biomedical Corporation Common Stock shares in Q2 2022, an estimated $74K.
  • Bank of New York Mellon first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 5 quarters.
  • Bank of New York Mellon's Talis Biomedical Corporation Common Stock position peaked at $1.03M in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.